Enhancing the Anti-Tumor Activity of breast Cancer-Specific Cytotoxic T Lymphocytes
Abstract
Directing the immune system to attack tumors represents a potential powerful non-toxic approach for the treatment of breast cancer. Our goal is to ultimately engineer the interleukin-2 receptor (IL- 2R) in cytotoxic T cells (CTL) to control signal transduction through this receptor and to improve the in vivo efficacy upon adoptive transfer to a tumor-bearing host. To this aim, we have continued to characterize a series of chimeric IL-2R constructs that depend upon drug-induced heterodimerization and prepare new constructs predicted to be more active as they are dependent upon homodimerization. We continue to refine our in vivo model of anti-tumor immunity. We show that naive CD8+ tumor-specific T cells very efficiently mediate anti-tumor responses independent of CD4+ helper cells.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2000
- Accession Number
- ADA387842
Entities
People
- Thomas Malek
Organizations
- University of Miami